Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO(TM) (Molnupiravir)

Business Wire February 24, 2023

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection

Accesswire February 22, 2023

Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection

Business Wire February 22, 2023

Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline

Business Wire February 21, 2023

Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO(TM) (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19

Business Wire February 21, 2023

U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck's PREVYMIS(TM) for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk

Business Wire February 17, 2023

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression

Business Wire February 16, 2023

Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium

Business Wire February 16, 2023

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma

Business Wire February 3, 2023

Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results

Business Wire February 2, 2023

FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)

Business Wire January 27, 2023

Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (fluralaner) Chews for Dogs

Business Wire January 26, 2023

Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility

Business Wire January 25, 2023

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial

Business Wire January 25, 2023

Merck Announces Second-Quarter 2023 Dividend

Business Wire January 24, 2023

Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort

PR Newswire January 17, 2023

Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.

Business Wire January 11, 2023

Merck Named One of America's Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech

Business Wire January 10, 2023

How Merck Is Prioritizing Diversity in Clinical Trials and Why It's So Important

Accesswire January 5, 2023

Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2

Business Wire January 5, 2023